Case Report

Anti-SARS-CoV-2 Antibody Level among Renal Transplant Recipients: A Case Report from Nepal

Kamal Ranabhat,1,2 Bhuvan Saud,3 Saroj Adhikari,4 Suraj Bhattarai,5 Rojan Adhikari,6 Bhoj Raj Luitel,1 and Mahesh Raj Sigdel1

1Institute of Medicine, Tribhuvan University, Kathmandu, Nepal
2Ministry of Health and Population, Kathmandu, Nepal
3Department of Medical Laboratory Technology, Janamaitri Foundation Institute of Health Sciences, Lalitpur, Nepal
4National Trauma Center, Ministry of Health and Population Kathmandu, Nepal
5Global Institute for Interdisciplinary Studies, Kathmandu, Nepal
6Shahid Dharma Bhakta National Transplant Center, Bhaktapur, Nepal

Correspondence should be addressed to Bhuvan Saud; link2bhuvan@gmail.com

Received 24 September 2021; Revised 10 December 2021; Accepted 22 December 2021; Published 10 January 2022

1. Introduction

Coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The virus causes significant morbidity and mortality in individuals with underlying clinical conditions. As of 8th January 2022, more than 302 million positive cases and 5.4 million deaths have been reported globally [1]. Generally, pathogenic microorganisms cause pathological manifestations in host system which depends on the host immune response and virulence factors of the infectious agents. Human body activates complex immune mechanism by which it provides protection from the invading foreign substance [2]. In SARS-CoV-2 infection, patients produce virus-specific B and T cells and then initially produce Immunoglobulin M (IgM) and later Immunoglobulin G (IgG) antibodies which are readily detected in serum [3, 4]. Generally, patients with chronic diseases are highly susceptible to the infection. Higher mortality rate in such group may be due to dysregulation of immune system. Studies have suggested that haemodialysis and kidney transplant patients are at high risk of mortality from SARS-CoV-2 with 20% mortality rate [5, 6]. Kidney transplant recipients are advised to take immune-suppressive drugs (calcineurin inhibitors, anti-proliferative agents, rapamycin inhibitors, and corticosteroids) in order to prevent rejection by the host immune system. Lowered immunity makes such person susceptible to infectious agents [7].

Globally, as of 7th January 2022, 137 different COVID-19 vaccines are in various phases of clinical trials, while
laboratory reports are listed in Table 1.

2.1. Patient 1. A 40-year-old overweight male had kidney transplant in 2008 (13 years ago). He received the first dose of ChAdOx1 nCoV-19 vaccine (AZD1222) on 1 June 2021 and the second dose on 8 July 2021. He did not experience COVID-19 infection. His blood was tested for anti-SARS-CoV-2 antibody level on 28 July 2021. Chemiluminescent immunoassay (CLIA) test report showed that anti-SARS-CoV-2 antibody level was 5.91 IU/ml, where test is positive if the value ranged >0.80 IU/ml. Other laboratory parameters are shown in Table 1.

2.2. Patient 2. A 38-year-old male had renal transplantation in 2006 (15 years ago). He took the first dose of ChAdOx1 nCoV-19 vaccine (AZD1222) on 1 June 2021 and the second dose on 8 July 2021. He did not experience COVID-19 infection. His blood was tested for anti-SARS-CoV-2 antibody level on 28 July 2021. Chemiluminescent immunoassay (CLIA) test report showed that anti-SARS-CoV-2 antibody level was 5.91 IU/ml, where test is positive if the value ranged >0.80 IU/ml. Other laboratory parameters are shown in Table 1.

2.3. Patient 3. A 41-year-old male had undergone kidney transplantation in 2006 (15 years ago). He took the first dose of ChAdOx1 nCoV-19 vaccine (AZD1222) on 1 June 2021 and the second dose on 8 July 2021. He did not experience COVID-19 infection. His blood was tested for anti-SARS-CoV-2 antibody level on 28 July 2021. Chemiluminescent immunoassay (CLIA) test report showed that anti-SARS-CoV-2 antibody level was 5.91 IU/ml, where test is positive if the value ranged >0.80 IU/ml. Other laboratory parameters are shown in Table 1.

3. Discussion

According to the report published by Shahid Dharma Bhakta National Transplant Center, Bhaktapur, annually, 3000 cases of kidney failure are reported in Nepal and out of them more than 350 kidney transplants are performed [14]. Kidney transplant recipients are at higher risk of microbial infection due to immunosuppressive status. In this case series, we present clinical and laboratory findings of three kidney transplant recipients in Nepal who were vaccinated against SARS-CoV-2 infection. The total leucocyte count and differential leucocyte count of all three cases were normal indicating that the therapeutic indices of the immune-suppressive medications had been maintained. Two recipients got infected by SARS-CoV-2 after completing two doses of vaccine but only presented mild symptomatic illness and successfully recovered without requiring critical care support. Mean age of transplant recipients was 39.6 (range, 38–41 years) and all three were male. Neutralizing antibody was developed in all three cases with significant antibody level. However, since the duration of protection from the vaccine is not clearly known yet, there is need for frequent follow-up for neutralizing antibody levels in such patients which is subjected to drop due to immune-suppressive medication. The result of this study is also different from other studies which reveal that very few individuals who received organ transplant developed anti-SARS-CoV-2 antibody [15, 16]. Kidney transplant recipients are at higher risk of developing COVID-19 severity if the recipients have comorbid diseases (obesity, diabetes, asthma, and chronic pulmonary disease), particularly diabetes and hypertension which are recognized as one of the main factors responsible for severity [16].

In this study, seroconversion occurred in all three transplant patients in an effective level. Studies have suggested that only 4-48% of renal transplant recipients have detectable anti-spike IgGs following two doses of COVID-19 vaccine [17]. In a study conducted among immune-suppressed solid organ transplant recipients from USA, who received Ad26.COV2.S (Janssen COVID-19 vaccine), out of 12 participants, only two (16%) had mounted detectable amount of antibody level [18]. A study from France conducted among kidney transplant recipients after administration of two doses of BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) found that 5.7% of the patients developed anti-spike antibodies [19]. Furthermore, a case control study conducted in Germany to evaluate the immune response after vaccination in kidney transplant recipients with
BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) found that only 22% of the recipients were positive for anti-SARS-CoV-2 IgG antibodies. The titers were also significantly lower than the control group of health-care workers. Anti-SARS-CoV-2 IgG antibodies were detected in 100% of the participants in the control group following vaccination [6]. The clinical outcome of the vaccinated renal transplant recipients in our study was favorable. Although two of the three patients got infected with COVID-19, both recovered and are stable. In a study conducted in India among four renal transplant recipients, all of them got infected with COVID-19 despite being vaccinated full doses of ChAdOx1 nCoV-19 vaccine (AZD1222); one of them died, two were admitted on ventilator at the time of the study, and another patient recovered and was stable at home [20].

Tacrolimus induces neutropenia [21] while mycophenolate mofetil leads to reduction of B-lymphocyte count [22]. It is important to maintain the circulating level of these drugs within therapeutic ranges to maintain health and prevent graft rejection. Both renal function tests and complete blood count profile are within normal range and the patients do not present any comorbidity which reflects that the immune-suppressant regimens are maintained within their therapeutic indices. The production of protecting level of humoral immune response against COVID-19 virus after vaccination in the study cases may be attributed to the maintained drug levels.

| Clinical variables               | Patient 1 | Patient 2 | Patient 3   |
|----------------------------------|-----------|-----------|-------------|
| Age                              | 40        | 38        | 41          |
| Gender                           | Male      | Male      | Male        |
| Transplant performed             | 2008      | 2005      | 2006        |
| Current medications              | Mycophenolate sodium 360 mg and tacrolimus 0.5 mg | Mycophenolate mofetil 500 mg and cyclosporine 25 mg | Mycophenolate mofetil 500 mg and tacrolimus (1 mg* and 0.5 mg**) |
| Body mass index                  | Overweight | Normal    | Overweight  |
| Comorbidities                    | No        | No        | Hypertension|
| 1st dose COVID vaccine           | 16 April 2021 | 21 April 2021 | 01 June 2021 |
| 2nd dose COVID vaccine           | 21 June 2021 | 08 June 2021 | 08 July 2021 |
| Serum creatinine (mg/dl)         | 1.3       | 1.4       | 1.2         |
| Serum urea (mg/dl)               | 41.0      | 16.96     | 21.0        |
| Sodium (Na⁺) mmol/l              | 136       | 139.0     | 143.0       |
| Potassium (K⁺) mmol/l            | 4.8       | 3.3       | 4.0         |
| Hemoglobin (g/dl)                | 15.8      | 12.6      | 12.7        |
| RBC (million/mm³)                | 5.48      | 4.64      | 4.76        |
| WBC (cells/mm³)                  | 7900      | 8400      | 12500       |
| Differential cell count          | Neutrophil (%) 78 | 74 | 77 |
|                                 | Lymphocyte (%) 16 | 21 | 21 |
|                                 | Monocyte (%) 04 | 4 | 02 |
|                                 | Eosinophil (%) 02 | 1 | 0 |
|                                 | Basophil (%) 0 | 0 | 0 |
| RT-PCR for COVID-19              | Positive  | Positive  | Not tested  |
| COVID-19 sign and symptoms       | Fever, body ache, and loss of smell | Fever, malaise, sore throat, and loss of smell and taste | Unknown |
| Anti-SARS-CoV-2 ab (method)      | 18.15 COI (ECLIA) | 54.5 (ELISA) | 5.91 U/ml (ECLIA) |
| Outcome                          | Recovered from COVID-19 | Recovered from COVID-19 | Stable |

Note. *Morning dose; **evening dose. NR: normal range; RT-PCR: reverse transcription polymerase chain reaction; ELISA: enzyme-linked immunosorbent assay; ECLIA: electrochemiluminescence immunoassay; ab: antibody; COI: cutoff index.
The limitations of this study are that antibody levels were not estimated periodically nor the antibody level was tested after first dose of vaccine administration. Another limitation is that only ChAdOx1 nCoV-19 (AZD1222) vaccinated individuals were enrolled in this study but the immune response to other types of COVID-19 vaccines might be different. Also, periodic reports of serum level of the immune-suppressive drugs could not be obtained which would have better justified the immune status of the participants in the study. For better evidence, similar serological studies should be conducted in large scale to understand the immunogenicity of newer vaccines in the immune-compromised population, the results of which would help the government and concerned authorities to take prompt action.

4. Conclusion

Protective level of humoral immune response against SARS-CoV-2 has been shown after administration of two doses of ChAdOx1 nCoV-19 (AZD1222) vaccine in renal transplant recipients. Routine monitoring of anti-SARS-CoV-2 circulating antibody as well as immune-suppressive drug level is recommended to understand the immune status of transplant recipients and the immunogenicity of newer vaccines in them.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request. The authors agree that anyone interested can have access to the raw data from the research upon request to the authors. The data will be provided to anyone based on two conditions: upon use of the data, the authors should be acknowledged and also the paper needs to be cited. An agreement in the aforementioned situation will be reached.

Consent

Written informed consent was obtained from the patients for publishing their case details along with their clinical, laboratory, and antibody details.

Disclosure

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Kamal Ranabhat and Bhuwan Saud conceptualized the study. Bhuwan Saud, Saroj Adhikari, and Kamal Ranabhat wrote the first draft and reviewed the literature. Mahesh Raj Sigdel, Suraj Bhattarai, Bhoj Raj Luitel, and Rojan Adhikari provided critical feedback to the draft. All authors read and approved the final version of the manuscript.

Acknowledgments

We thank the patients and their family members for their cooperation and for the written informed consent for the publication of this case report. We acknowledge Mr. Himalaya Tiwari, health staff, Bir Hospital, for his invaluable support and coordination.

References

[1] John Hopkins University and Medicine, Coronavirus Resource Centerhttps://coronavirus.jhu.edu/.
[2] C. Wang, X. Zhou, M. Wang, and X. Chen, "The impact of SARS-CoV-2 on the human immune system and microbiome," Infectious Microbes & Diseases, vol. 3, no. 1, p. 14, 2021.
[3] P. D. Burbelo, F. X. Riedo, C. Morishima et al., "Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019," The Journal of infectious diseases, vol. 222, no. 2, pp. 206–213, 2020.
[4] J. Qu, C. Wu, X. Li et al., "Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)," Clinical Infectious Diseases, vol. 71, no. 16, pp. 2255–2258, 2020.
[5] C. Hugo, M. Stecher, S. Dolf et al., "Solid organ transplantation is not a risk factor for COVID-19 disease outcome," Transplant international: official journal of the European Society for Organ Transplantation, vol. 34, no. 2, pp. 378–381, 2021.
[6] J. Korth, M. Jahn, O. Dorsch et al., "Impaired humoral response in renal transplant recipients to SARS-CoV-2 vaccination with BNT162b2 (Pfizer-BioNTech)," Viruses, vol. 13, no. 5, p. 756, 2021.
[7] A. Ortiz, M. Cozzolino, R. Duivenvoorden et al., "Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA," Nephrology Dialysis Transplantation, vol. 36, no. 1, pp. 87–94, 2021.
[8] WHO, Draft landscape and tracker of COVID-19 candidate vaccines, World Health Organization 2021a, 2021, June 2021 https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
[9] "Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients," Journal of the American Medical Association, vol. 325, pp. 1784–1786, 2021.
[10] T. Kolb, S. Fischer, L. Müller et al., "Impaired immune response to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients," Kidney, vol. 2, no. 9, pp. 1491–1498, 2021.
[11] L. Danziger-Isakov, D. Kumar, and AST ID Community of Practice, "Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice," Clinical Transplantation, vol. 33, no. 9, p. e13563, 2019.
[12] N. Toapanta, O. Bestard, and M. J. Soler, "SARS-CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response?"
I. Benotmane, G. Gautier-Vargas, N. Cognard et al., "Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients," *Kidney international*, vol. 99, no. 6, pp. 1487–1489, 2021.

"Human Organ Transplant Center," https://hotc.org.np/.

M. Elias, D. Pievani, C. Randoux et al., "COVID-19 infection in kidney transplant recipients: disease incidence and clinical outcomes," *Journal of the American Society of Nephrology*, vol. 31, no. 10, pp. 2413–2423, 2020.

D. Banerjee, J. Popoola, S. Shah, I. C. Ster, V. Quan, and M. Phanish, "COVID-19 infection in kidney transplant recipients," *Kidney international*, vol. 97, no. 6, pp. 1076–1082, 2020.

S. Caillard and O. Thaunat, "COVID-19 vaccination in kidney transplant recipients," *Nature Reviews. Nephrology*, vol. 17, pp. 785–787, 2021.

B. J. Boyarsky, T. P. Chiang, M. T. Ou et al., "Antibody response to the Janssen COVID-19 vaccine in solid organ transplant recipients," *Transplantation*, vol. 105, no. 8, pp. e82–e83, 2021.

N. Chavarot, A. Ouedrani, O. Marion et al., "Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept," *Transplantation*, vol. 105, no. 9, pp. e94–e95, 2021.

H. S. Meshram, V. B. Kute, N. Shah et al., "COVID-19 in kidney transplant recipients vaccinated with Oxford–AstraZeneca COVID-19 vaccine (Covishield): a single-center experience from India," *Transplantation*, vol. 105, no. 9, 2021.

A. De Rycke, D. Dierickx, and D. R. Kuypers, "Tacrolimus-induced neutropenia in renal transplant recipients," *Clinical Journal of the American Society of Nephrology*, vol. 6, no. 3, pp. 690–694, 2011.

G. Weigel, A. Griesmacher, A. Karimi, A. O. Zuckermann, M. Grimm, and M. M. Mueller, "Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients," *The Journal of heart and lung transplantation*, vol. 21, pp. 1074–1079, 2002.